Drug Database
CI

cilostazol + ginko biloba extract (Rinexin / SID142 / SID 142)

✓ Approved

SK Chemicals · therapeutic agent

What is cilostazol + ginko biloba extract?

cilostazol + ginko biloba extract is a therapeutic agent developed by SK Chemicals. It is approved for therapeutic indications via unknown.

Drug Profile

Brand NamesRinexin, SID142, SID 142
CompanySK Chemicals
RouteUnknown
StatusApproved
Sources: ClinicalTrials.gov, SK Chemicals

Therapeutic Indications

cilostazol + ginko biloba extract is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Vascular disordersPeripheral vascular disorder✓ Approved

Related Research Articles

PubMedJournal of oral biology and craniofacial research2026-08-30

Influence of matrix metalloproteinase inhibitors on resin-dentin bond strength and hybrid-layer characteristics of caries-affected dentin using a universal adhesive system.

Dhatavkar Prasanna P, Aggarwal Shalini S, Kesharani Pooja P, Borkar Anamika A

Matrix metalloproteinase-mediated collagen degradation compromises the durability of resin-dentin bonds, particularly in caries-affected dentin. Natural matrix metalloproteinase (MMP) inhibitors have gained attention as biocompatible alternatives to conventional synthetic agents for improving adhesive stability. To evaluate the effects of natural and synthetic MMP inhibitors on microtensile bond strength and failure patterns in caries-affected dentin bonded with a universal adhesive using etch-and-rinse and self-etch modes. A total of 240 extracted human permanent molars with artificially induced caries-affected dentin were allocated to 16 subgroups according to pretreatment agent and bonding mode. The pretreatment agents included grape seed extract, green tea extract, riboflavin, cranberry extract, chlorhexidine, doxycycline, sodium fluoride, and no inhibitor. A universal adhesive and nanohybrid composite resin were applied according to the assigned etch-and-rinse or self-etch protocol. Microtensile bond strength was measured using a universal testing machine. Data were analyzed using one-way analysis of variance, chi-square test, and Pearson correlation coefficient at a significance level of 0.05. Etch-and-rinse bonding produced significantly greater bond strength than self-etch bonding. Grape seed extract and green tea extract showed the highest bond-strength values, followed by riboflavin and cranberry extract. Chlorhexidine, doxycycline, and sodium fluoride showed limited improvement. Adhesive failure predominated the association with bond strength. Etch-and-rinse application of a universal adhesive combined with natural matrix metalloproteinase inhibitors, especially grape seed and green tea extracts, enhanced resin-dentin bond strength in caries-affected dentin.

PMID 42668588
Read full article →
PubMedPharmaceutical science advances2026-08-30

Corrigendum to "Metabolomic profiling of Musanga cecropioides leaf extract reveals cytotoxic mechanisms in MCF-7 breast cancer cells" [Pharm. Sci. Adv. 4 (2026) 100107].

Olaleye Olubusola O OO, Kim Dong-Hyun DH, Spriggs Keith A KA

[This corrects the article DOI: 10.1016/j.pscia.2025.100107.].

PMID 42668643
Read full article →
PubMedCureus2026-08-30

Real-World Efficacy and Safety of a Topical Salvia fruticosa Leaf Extract Rich in Carnosic Acid and Carnosol for Mild to Very Severe Facial Seborrheic Dermatitis: A 12-Year Retrospective Study.

Kallimanis Panagiotis P, Prodromidis Serafim S

Objective We aimed to evaluate the safety and efficacy of a cream (SDπ) containing S. fruticosa leaf extract rich in carnosic acid and carnosol in the treatment of facial seborrheic dermatitis (SD). Methods In this 12-year retrospective study, 10 patients (eight males, two females; age range, 40-78 years) with mild to very severe facial seborrheic dermatitis (mean baseline Seborrheic Dermatitis Area and Severity Index (SEDASI) score: 19; range, 10-60) applied SDπ cream once nightly as monotherapy. Follow-up ranged from 6 months to 5 years. Results All patients achieved complete disease clearance (SEDASI=0) within a mean of 7.7 days (range 3-15 days) with marked reduction in erythema, scaling, and rapid relief of pruritus. Remission persisted from 20 days to 10 months. Subsequent episodes responded to re-treatment in a shorter period (mean 4.8 days), while no relapses were observed during long-term maintenance therapy with nightly or alternate-night application. No local or systemic safety concerns were documented throughout treatment and the longitudinal follow-up period. Conclusions In this retrospective observational study, SDπ cream was associated with favorable clinical outcomes and good tolerability, suggesting that it may represent a promising natural topical monotherapy for facial seborrheic dermatitis. Although these findings are encouraging, prospective randomized controlled studies are required to confirm efficacy and long-term safety. To our knowledge, this work represents the first full-length retrospective report in the literature documenting the therapeutic role of S. fruticosa leaf extract rich in carnosic acid and carnosol in seborrheic dermatitis.

PMID 42668826
Read full article →
PubMedChemical communications (Cambridge, England)2026-08-30

Mapping conformational heterogeneity: 19F-Gd3+ ENDOR reveals otherwise hidden rotamer conformations.

Habel Edan E, Judd Martyna M, Huber Thomas T, Cox Nicholas N

19F-Gd3+ ENDOR is used to map the full conformational distribution of Trp42 in dihedral space in a de novo luminescent lanthanide-binding protein. By combining genetically encoded fluorination with regularisation modelling, we extract 19F-Gd3+ distance distributions, revealing a minor rotamer population proximal to the lanthanide, key for photoactivity.

PMID 42669308
Read full article →
PubMedJournal of molecular histology2026-08-30

Anti-inflammatory, wound healing, and hepatoprotective effects of Acampe papillosa (Lindl.) Lindl. seed in wistar rats: insights from biochemical, histopathological, and in silico investigations.

Nujhat Nusaiba N, Payel Inun Nahar IN, Ali Md Liakot ML, Mukta Rowshan Akter RA et al.

Acampe papillosa (Lindl.) Lindl. has long been used to cure a variety of illnesses, including rheumatism and traumatic tissue injuries. Nevertheless, there is a dearth of comprehensive information on its phytochemical composition and pharmacological actions. Therefore, here, we present the first thorough pharmacological and histopathological analysis of Acampe papillosa seed methanolic extract (ME-APS), together with in silico molecular docking studies, hepatoprotective, wound-healing, and anti-inflammatory properties. Before pharmacological evaluations, safety was assessed through oral and dermal toxicity studies. The anti-inflammatory activity of ME-APS was tested using carrageenan and formalin-induced paw oedema models, and the wound healing potential was observed using incision and excision wound models. Hepatoprotective activity was studied in the CCl4-induced hepatotoxicity model in rats. In oral (up to 5000 mg/kg) and dermal (10% ointment formulation) toxicity studies, ME-APS was found to be safe with no visible signs of toxicity. In the study on anti-inflammatory properties, ME-APS significantly reduced paw oedema in carrageenan and formalin models of inflammation. Wound healing assays showed that the extract significantly improved wound contraction, tensile strength, epithelialization, collagen deposition, and fibroblast proliferation in a dose-dependent way. The hepatoprotective study showed that ME-APS treatment significantly restored the altered biochemical parameters, such as ALT, AST, TC, TG, and LDL levels, and ameliorated CCl4-induced histopathological liver damage. Further, the molecular docking study showed that the major phytochemicals in the extract, such as squalene, cholesta-4,6-dien-3-ol (3β), stigmasterol, and γ-sitosterol, showed significant binding affinities for COX-2 and TGF-β-related targets involved in inflammation, wound healing, and hepatoprotection. Additionally, a high probability of biological efficacy was predicted using PASS (Prediction of Activity Spectra for Substances) analysis. Overall, the findings suggest that ME-APS has possible anti-inflammatory, wound healing, and hepatoprotective activities that support its traditional medicine use and imply that it is a potential source of therapeutic phytochemicals.

PMID 42669114
Read full article →
PubMedThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026-08-30

Tackling Drug Resistance and Virulence in Proteus mirabilis Infections: Evaluating Rosemary Extract as a Complementary Therapeutic Agent.

Mirzaei Arezoo A, Wagemans Jeroen J, Moghim Sharareh S

The rising antimicrobial resistance in Proteus mirabilis, a primary contributor to catheter-associated urinary tract infections, underscores the urgent need to explore alternative therapeutic approaches. In this study, we evaluated the antibacterial and antivirulence potential of Rosmarinus officinalis L. extract (ROE) against P. mirabilis and concurrently assessed clinical isolates for the presence of key resistance and virulence genes. Forty multi-drug-resistant (MDR) P. mirabilis isolates were analyzed using multiplex PCR to detect carbapenemase genes (b l a NDM, b l a OXA family, b l a SIM-1, b l a VIM-1) and uniplex PCR to identify virulence determinants (mrpA, pmfA, rsbA, rsmA, luxS). ROE was extracted and analyzed using high-performance liquid chromatography (HPLC). The antibacterial, antibiofilm, and antiswarming effects of the extract were assessed. All isolates carried all five virulence genes. Carbapenemase gene profiling revealed b l a VIM-1in 20% of isolates, while b l a OXA-23, b l a OXA-24, and b l a OXA-58 were detected in 10%, 2.5%, and 2.5% of isolates, respectively. Neither b l a SIM-1 nor b l a NDM was identified. HPLC analysis of ROE identified rosmarinic acid as the predominant compound. Although the agar well diffusion assay indicated no bactericidal activity, the broth microdilution method determined a minimum inhibitory concentration (MIC) of 8 mg/mL for both reference and MDR strains. At sub-MIC levels, ROE significantly inhibited swarming motility (up to 86% at 250 μg/mL) and biofilm formation (up to 78% in the reference strain and 76% in MDR isolates at 15.6 μg/mL) in a dose-dependent manner. Notably, biofilm eradication activity was observed only against preformed biofilms of the reference strain, achieving up to 53% reduction. MTT cytotoxicity assays confirmed that ROE in low concentrations (1000-15.6 μg/mL) was nontoxic to Vero cells. These results highlight the concerning prevalence of carbapenemase genes among clinical P. mirabilis isolates and identify ROE as a promising, nontoxic candidate for targeting motility and biofilm formation. These findings suggest ROE may offer a viable strategy for managing drug-resistant P. mirabilis infections.

PMID 42668901
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about cilostazol + ginko biloba extract